Abstract
Topiramate-induced acute angle closure is a well-known entity with onset of symptoms at 2 weeks following treatment initiation. We report a 24-year-old female with blurring of vision 2 days after increasing the topiramate dose for migraine prophylaxis. Examination showed increase in manifest myopia with normal intraocular pressure and absence of angle closure. Provisional diagnosis of topiramate-induced myopia (TIM) was made, confirmed by presence of uveal effusion on B-scan and ultrasound biomicroscopy. Early presentation during the course could be the reason for isolated myopia. She was advised to stop topiramate and was started on cycloplegics. This case highlights that awareness about TIM among patients helps in prompt management, thus preventing the site-threatening acute angle closure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
